Rachiglio, A. M., Fenizia, F., Piccirillo, M. C., Galetta, D., Crinò, L., Vincenzi, B., . . . Normanno, N. (2019). The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers (Basel).
Dyfyniad Arddull ChicagoRachiglio, Anna Maria, et al. "The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients." Cancers (Basel) 2019.
Dyfyniad MLARachiglio, Anna Maria, et al. "The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients." Cancers (Basel) 2019.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.